SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Axial view of the brain showing a glioblastoma in the left frontal lobe with central necrosis, peripheral infiltration, and early midline shift.
Brain cancer
FDA Greenlights Jazz’s Dordaviprone, First New Treatment for Ultra-Rare Brain Tumor
The small molecule drug, acquired by Jazz Pharmaceuticals in its $935 million Chimerix pick-up this spring, is intended for relapsed adult and pediatric patients with H3 K27M mutations.
August 6, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Bayer's factory and office in Berlin
Earnings
Bayer Expects More Layoffs To Come Following a Brutal Two Years of Cost-Cutting
The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July 2023. Bayer said even more cuts are coming as it weathers up-and-down sales across its portfolio.
August 6, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Difference thinking concept.
Earnings
Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market
Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.
August 6, 2025
 · 
2 min read
 · 
Annalee Armstrong
Assembling jigsaw puzzle. Organizing business people hierarchy.
Earnings
‘Execution, Execution, Execution’: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline
Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of reallocating resources to the company’s “main core” of metabolic disease.
August 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Tariffs
Trump Threatens Highest Pharma Tariffs So Far at 250%
President Donald Trump plans to start with a “small tariff” on pharmaceutical imports before ramping duties up to 250% within a year and a half.
August 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Biontech SE headquarters with company flags, German biotechnology company, BioNTech Manufacturing, development and production active immunotherapeutic agents in Mainz, Germany - September 7, 2024
Layoffs
BioNTech Cuts 90 Jobs Amid ‘Strategic Alignment’
BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing operations in Gaithersburg, Maryland.
August 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Health and Human Services Secretary Robert F. Kennedy Jr. makes remarks at an event announcing the MAHA (Make America Healthy Again) Commission, Thursday, May 22, 2025, in the East Room of the White House. (Official White House Photo by Joyce N. Boghosian)
Vaccines
RFK Jr. Axes 22 mRNA Vaccine Projects Under BARDA
The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA vaccine development, a move that will affect several pharma companies, including Moderna, Pfizer, Sanofi and AstraZeneca.
August 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Close-up image of human hand holding wrench. Construction
Earnings
Biopharma CEOs Can’t Dodge Policy Questions as Trump Lobs Wrench into Earnings Season
From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.
August 6, 2025
 · 
6 min read
 · 
Annalee Armstrong
Podcast
FDA In Flux, Pfizer Talks to Trump on MFN, Merck Cuts 6K Jobs, More
George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest rejection reportedly driven by FDA’s top cancer regulator Richard Pazdur; Merck’s $3 billion savings push claims 6,000 jobs; and Pfizer CEO Albert Bourla addresses President Donald Trump’s new threats around Most Favored Nation drug pricing.
August 6, 2025
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS